TW202234999A - 包含發酵熟成諾麗及卡曼橘作為活性成分的組合物用於釋放壓力 - Google Patents
包含發酵熟成諾麗及卡曼橘作為活性成分的組合物用於釋放壓力 Download PDFInfo
- Publication number
- TW202234999A TW202234999A TW110149147A TW110149147A TW202234999A TW 202234999 A TW202234999 A TW 202234999A TW 110149147 A TW110149147 A TW 110149147A TW 110149147 A TW110149147 A TW 110149147A TW 202234999 A TW202234999 A TW 202234999A
- Authority
- TW
- Taiwan
- Prior art keywords
- noni
- fermented
- extract
- composition
- matured
- Prior art date
Links
- 244000131360 Morinda citrifolia Species 0.000 title claims abstract description 84
- 235000017524 noni Nutrition 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 239000004480 active ingredient Substances 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 title claims description 86
- 241000369096 Citrus x microcarpa Species 0.000 title abstract description 3
- 235000000346 sugar Nutrition 0.000 title description 3
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 235000013402 health food Nutrition 0.000 claims abstract description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 22
- 235000020729 noni extract Nutrition 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 15
- 239000004310 lactic acid Substances 0.000 claims description 15
- 235000014655 lactic acid Nutrition 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 14
- 229960000890 hydrocortisone Drugs 0.000 abstract description 9
- 229940076279 serotonin Drugs 0.000 abstract description 7
- 229940088597 hormone Drugs 0.000 abstract description 5
- 239000005556 hormone Substances 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 239000002438 stress hormone Substances 0.000 abstract description 3
- 230000002180 anti-stress Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000035882 stress Effects 0.000 description 47
- 150000001875 compounds Chemical class 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000010171 animal model Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 235000013399 edible fruits Nutrition 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 208000013200 Stress disease Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 6
- 241000675108 Citrus tangerina Species 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- -1 glycoside compounds Chemical class 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Chemical class 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 240000008866 Ziziphus nummularia Species 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZVXWFPTVHBWJOU-AWQYILTISA-N (1s,4as,5r,7as)-5-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C(C(O)=O)=CO1 ZVXWFPTVHBWJOU-AWQYILTISA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- VKWWRUZYBNTDHM-AXECJBQYSA-N Deacetylasperulosidic acid Natural products OCC1=C[C@H](O)[C@H]2[C@@H]1[C@H](OC[C@H]3O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]3O)OC=C2C(=O)O VKWWRUZYBNTDHM-AXECJBQYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- BZPMXJKRKXDRID-UOIKKKDVSA-N Scandoside Natural products OC[C@H]1O[C@@H](O[C@H]2CC=C([C@@H]3[C@@H](O)C=C(CO)[C@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O BZPMXJKRKXDRID-UOIKKKDVSA-N 0.000 description 2
- MEGPURSNXMUDAE-UHFFFAOYSA-N Scopoline Natural products C1C(O2)CC3N(C)C1C2C3O MEGPURSNXMUDAE-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- IBIPGYWNOBGEMH-DILZHRMZSA-N asperuloside Chemical compound O([C@@H]1OC=C2C(=O)O[C@H]3C=C([C@@H]1[C@H]32)COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBIPGYWNOBGEMH-DILZHRMZSA-N 0.000 description 2
- COUXBBBIXWWAEP-AGUBZPQCSA-N asperuloside Natural products CC(=O)OCC1=C[C@@H]2OC(=O)C3=CO[C@@H](OC[C@H]4O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]4O)[C@H]1[C@H]23 COUXBBBIXWWAEP-AGUBZPQCSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- WBAVLTNIRYDCPM-UHFFFAOYSA-N isoscopolin Natural products COC1=CC=2OC(=O)C=CC=2C=C1OC1OC(CO)C(O)C(O)C1O WBAVLTNIRYDCPM-UHFFFAOYSA-N 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000011814 protection agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- SGTCGCCQZOUMJJ-YMILTQATSA-N scopolin Chemical compound COC1=CC=2C=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SGTCGCCQZOUMJJ-YMILTQATSA-N 0.000 description 2
- SGTCGCCQZOUMJJ-UHFFFAOYSA-N scopolin Natural products COC1=CC=2C=CC(=O)OC=2C=C1OC1OC(CO)C(O)C(O)C1O SGTCGCCQZOUMJJ-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Chemical class 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical compound CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- DGDWCRWJRNMRKX-DILZHRMZSA-N Asperulosidic acid Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)[C@@H](O)C=C2COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGDWCRWJRNMRKX-DILZHRMZSA-N 0.000 description 1
- DGDWCRWJRNMRKX-UHFFFAOYSA-N Asperulosidinsaeure Natural products CC(=O)OCC1=CC(O)C(C(=CO2)C(O)=O)C1C2OC1OC(CO)C(O)C(O)C1O DGDWCRWJRNMRKX-UHFFFAOYSA-N 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000234653 Cyperus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 244000010000 Hovenia dulcis Species 0.000 description 1
- 235000008584 Hovenia dulcis Nutrition 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000000365 Oenanthe javanica Nutrition 0.000 description 1
- 240000006243 Oenanthe sarmentosa Species 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- AHFAQKUDQUDLNP-AGUBZPQCSA-N asperulosidic acid Natural products CC(=O)OCC1=C[C@H](O)[C@H]2[C@@H]1[C@H](OC[C@H]3O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]3O)OC=C2C(=O)O AHFAQKUDQUDLNP-AGUBZPQCSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003131 corticotrophic effect Effects 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000001369 pituitary-adrenal system Anatomy 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229930195350 pyrroside Natural products 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/231—Lactis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
Abstract
本發明係有關於壓力釋放用食品組合物,具體地係有關於作為活性成分包含發酵熟成諾麗及卡曼橘,降低作為壓力激素的皮質醇(Cortisol)的分泌,增加作為快樂激素的血清素(Serotonin)的分泌,無副作用,對人體安全的壓力釋放用食品組合物,其可包含在保健食品或藥學組合物中使用。本發明的組合物的抑制壓力的抗壓力效果優秀。
Description
本發明係有關於作為活性成分包含發酵熟成諾麗及卡曼橘的組合物,更詳細地,係有關於作為活性成分包含發酵熟成諾麗及卡曼橘,來釋放壓力,並可預防及改善因壓力引起的症狀的組合物。
所謂萬病之源的壓力,存在於人或動物的所有生活的領域。壓力是強烈的刺激,其因日常生活中感受的小事至大受打擊的主要事件為止的多種因素而誘發,通過這種壓力的刺激誘發疲勞和厭倦感、抑鬱感等,並引發內在·外在負面反應。
通常對身體帶來的刺激為規定程度以上時,會對身體帶來損傷,此時生物體與其刺激的種類無關地以針對規定威脅的反應呈現非特異性全身適應綜合征(general adaptative syndrome),這種現象被稱為壓力。這種壓力有多種,作為其例子有緊張性頭痛、偏頭痛、高血壓、消化不良、疲勞、痛症、更年期障礙、脫髮、皮膚的粗糙。並且,若壓力慢性持續,則呈現各種神經症、胃潰瘍等,身體的生理活性、免疫活性等降低,壓制精神活動,導致情緒不穩定,還誘發異常行動。
尤其,由於在現代社會上過度產生壓力,因此壓力突顯為非常重要的社會問題。
誘發壓力的原因和其身體的變化多樣,但是共同導致作為交感神經系統的腦垂體-腎上腺系統(HPA)的功能亢進,誘發激素分泌,致使腎上腺的功能亢進和脾臟的功能減退,其結果可知出現因壓力引起的所有症狀。若壓力加重,則脾臟因免疫功能的減退而導致重量顯著降低,通過促腎上腺皮質激素使腎上腺的功能亢進,重量增加,出現脂質減少現象,促進皮質醇(cortisol)的分泌。皮質醇的量處於根據年齡及壓力增加的傾向,這又為肥胖做貢獻。並且,若壓力加重,則腎上腺分泌激素,在血液內增加膽固醇、血糖、乳酸脫氫酶(lactate dehydrogenase:LDH)等。
另一方面,對於與壓力深度相關的胃潰瘍而言,據悉活性氧簇與這種消化器官的潰瘍生成相關。用於去除活性氧或活性氧簇(Reactive Oxygen Species;ROS)的生物防禦系統大體上區分為基於超氧化物歧化酶(superoxide dismutase;SOD)、過氧化氫酶(catalase)、穀胱甘肽過氧化物酶(glutathione peroxidase)等酶系統的酶防禦系統和中斷或結束ROS或自由基的連鎖反應的非酶防禦系統。利用氧的生物體具有去除超氧化物(superoxide)的酶即SOD,保護生物體不受超氧化物引起的損傷。過氧化氫酶呈現去除在組織內通過SOD等酶反應生成的H
2O
2,來防禦生物體的功能。並且,據報導,不僅去除代謝過程中產生的活性氧簇的游離基,而且通過這些活性氧還可以不可逆地失活,還去除通過脂質氧化生成的游離基。動物組織中佔據大部分非蛋白硫醇(thiol)的穀胱甘肽(GSH,glutathione)起到游離基去除劑作用,作為使H
2O
2及過氧化脂質的GSH-Px的基質,起到細胞內抗氧化劑的重要作用(Cho SY.et al., J. Korean Soc. Food Sci. Nutr., 32(3), pp458-463, 2003)。
近來,為了解除壓力而尋求多種方法,最有效的方法利用運動或心理治療等。並且,還存在根據壓力的強度來並行藥物治療,使壓力帶來的受害最小化的方法。尤其,作為用於釋放壓力的藥物,利用作為神經安定劑的苯二氮平、作為精神安定劑的鎮靜劑之類的精神藥物等。
但是,為了釋放壓力,利用如上的安定劑時,存在中毒的危險性,在合成藥品的特性上存在難以排除副作用的問題。過度依賴藥物反而引起另一種壓力的方面上存在負面影響。
最近,開展多項利用中草藥材料開發出於疲勞恢復或壓力釋放目的的食品。
利用天然中醫藥材的疲勞恢復用組合物的相關研究當中,在韓國公開專利第10-2000-0066777號(公開日期為2002年05月16日)中公開了利用提取川芎、甘草、葛根、枳椇子、赤楊、陳皮、大棗、水芹菜及銀杏葉的提取液的功能性飲料,在韓國公開專利第10-2005-0108856號(公開日期為2005年11月17日)中公開了包含黃精、麥門冬、枸杞子、五味子的疲勞恢復用藥膳飲料。
壓力解除用食品的相關研究當中,在韓國公開專利第10-2004-0006705號(公開日期為2004年01月24日)中公開了將深層水、有機鍺及香附子、陳皮、麥芽、酸棗仁、大棗作為必需成分的壓力解除用保健食品,在韓國公開專利第10-2004-0018888(公開日期為2004年03月04日)號中公開了將紅參、天麻、生地黃汁等作為主原料的壓力解除食品。並且,在韓國公開專利第10-2005-0080455號(公開日期為2005年08月12日)中公開了以往的四君子湯中追加梅子、玉竹、葛根、桂皮提取物的具有抗壓力效果的加味四君子湯。
據悉,自然界中存在的植物中大量含有具有防止疾病和抑制老化等生物調節功能的功能性成分,由此正在活躍進行有關天然食品原材料的研究。
因此,最近正在活躍進行利用如植物提取物一樣安全性得到保障的天然物來開發功能性補助劑的研究。對此,本發明人持續進行有關發酵熟成諾麗及卡曼橘的研究的結果,確認了這些複合物的攝取對壓力的釋放有效,由此完成了本發明。
[現有技術文獻](專利文獻)
(專利文獻1)韓國公開專利第2000-0066777號
(專利文獻2)韓國公開專利第10-2005-0108856號
[發明要解決的技術問題]
本發明的目的在於,解決前述問題及與其相關的其他問題。
本發明的目的在於,在可有效釋放壓力的天然成分組合物相關研究中確認包含發酵熟成諾麗及卡曼橘的複合組合物具有壓力釋放活性,由此完成了本發明。
本發明的一目的在於,提供包含發酵熟成諾麗或其提取物及卡曼橘提取物作為活性成分的組合物用於釋放壓力。
本發明的另一目的在於,提供作為活性成分包含發酵熟成諾麗或其提取物及卡曼橘提取物的組合物的製備方法。
本發明的另一目的在於,提供包含發酵熟成諾麗及卡曼橘作為活性成分的食品組合物用於釋放壓力。
本發明的另一目的在於,提供包含發酵熟成諾麗及卡曼橘作為活性成分的藥學組合物用於釋放壓力。
本發明的另一目的在於,提供包含發酵熟成諾麗及卡曼橘作為活性成分的醫藥外品組合物用於釋放壓力。
本發明的另一目的在於,提供包含發酵熟成諾麗及卡曼橘作為活性成分的飼料組合物用於釋放壓力。
要根據本說明書中公開的發明技術思想來實現的技術問題,並不限定於用於解決以上提及的問題的技術問題,本發明的普通技術人員可通過以下的記載明確理解未被提及的另一技術問題。
[本發明的技術方案]
對其進行具體說明如下。另一方面,本申請中公開的各個說明及實施方式也可適用於各個其他說明及實施方式。即,本申請中公開的多種因素的所有組合屬於本申請的範疇中。並且,本申請的範疇不得被視為限定於以下描述的具體說明。
為了解決如上的問題,本發明提供作為活性成分包含發酵熟成諾麗或其提取物及卡曼橘提取物的壓力釋放用或壓力疾病的預防或治療用組合物。
以下,詳細說明本發明。
在本發明中,“發酵熟成諾麗”是指在諾麗中接種乳酸菌而發酵及熟成的諾麗。其中,諾麗不受其部位的限制,但是作為一個示例可使用諾麗果。
“發酵諾麗”可以是在諾麗果中接種以下7種乳酸菌中的任一個以上的發酵物:
(1)植物乳桿菌(Lactobacillus plantarum);
(2)副乾酪乳桿菌(Lactobacillus paracasei);
(3)鼠李糖乳桿菌(Lactobacillus rhamnosus);
(4)乾酪乳桿菌(Lactobacillus casei);
(5)發酵乳桿菌(Lactobacillus fermentum);
(6)羅伊氏乳桿菌 (Lactobacillus reuteri);以及
(7)乳酸乳球菌乳酸亞種(Lactococcus lactis subsp. lactis)。
上述“發酵諾麗”利用生物轉化能力優秀的乳酸菌來發酵,其可將作為諾麗中所含的配糖體化合物的東莨菪甙(Scopolin)、車葉草甙(Asperuloside)生物轉化為作為非配糖體化合物的東莨菪素(scopoletin)、去乙醯車葉草苷酸(deacetylasperulosidic acid,DAA)及車葉草苷酸(asperulosidic acid)。
上述“發酵諾麗”提取物中所含的生物轉化的東莨菪素的含量為1~200mg/mL,去乙醯車葉草苷酸的含量為0.2~0.6mg/mL,車葉草苷酸的含量為0.096~1.41mg/mL。在分析範圍誤差內,發酵熟成諾麗中也同樣含有發酵諾麗中所含的東莨菪素、去乙醯車葉草苷酸、車葉草苷酸的含量。
本發明的“發酵熟成諾麗”可以是發酵熟成諾麗本身或從中獲得的提取物。 例如,本發明的發酵熟成諾麗可以是在諾麗果接種乳酸菌而發酵及熟成,並將這些發酵熟成的發酵熟成諾麗榨汁而獲得液的提取物。
卡曼橘(Calamansi)是熱帶性水果,其為東南亞地區栽培的果實。上述卡曼橘提取物是指從上述卡曼橘中提取果汁的,果汁的提取方法是以往充分公知的事項,故而省略其詳細說明。並且,還可以購買市面上銷售中的卡曼橘原液來使用,而不是額外製備提取物。上述卡曼橘比起檸檬,維生素C的含量為30倍以上,並大量含有隱黃素(cryptoxanthin)、橙皮甙(hesperidin)、川陳皮素(nobiletin)、西涅護林(cinehulin)等。
在本說明書中,“提取物”是指在本領域中通用為粗提取物(Crude extract)的意思,但是在廣義上還包含將提取物進一步分餾(Fractionation)的分餾物的意思。即,發酵熟成諾麗或其提取物及卡曼橘提取物,不僅包含利用上述提取溶劑來獲得的提取物,還包含在此追加適用精製過程獲得的提取物。例如,使上述提取物經由具有規定的分子量截留(cut off)值的超濾膜而獲得的分餾、通過基於多種層析(大小、電荷、為了基於疏水性或親和性的分離而製備的)的分離等追加實施的多種純化方法獲得的分餾也包括在本發明的發酵熟成諾麗及卡曼橘提取物中。
在本說明書中,“活性成分”是指包含實現發酵熟成諾麗或其提取物及卡曼橘提取物的功效或活性時充分的量。本發明是從作為天然植物材料的發酵熟成諾麗及卡曼橘中提取的組合物,由於過量給藥也對人體無副作用,因此發酵熟成諾麗及卡曼橘提取物包含在本發明的組合物的量的上限可由普通技術人員在適當的範圍內選擇而實施。
根據本發明的發酵熟成諾麗及卡曼橘提取物是利用有機溶劑來提取的,作為提取溶劑可使用的溶劑為如下。
首先,適合作為極性溶劑的有(i)水,(ii)碳原子數為1至6醇(較佳地,甲醇、乙醇、丙醇、丁醇、正丙醇、異丙醇、正丁醇、1-戊醇、2-丁氧基乙醇或乙二醇),(iii)乙酸,(iv)二甲基甲醯胺(DMFO,Dimethyl-formamide)及(v)二甲基亞碸(DMSO,Dimethyl sulfoxide)等。
並且,適合作為非極性溶劑的有丙酮、乙腈、乙酸乙酯、乙酸甲酯、氟代烷、戊烷、己烷、2,2,4-三甲基戊烷、癸烷、環己烷、環戊烷、二異丁烯、1-戊烯、1-氯丁烷、1-氯戊烷、o-二甲苯、二異丙基醚、2-氯丙烷、甲苯、1-氯丙烷、氯苯、苯、二乙醚、二乙基硫醚、氯仿、二氯甲烷、1,2-二氯乙烷、苯胺、二乙胺、醚、四氯化碳、二氯甲烷、石油醚及四氫呋喃(THF)等。
作為本發明的提取溶劑的代表性的示例,較佳地使用(a)水,(b)碳原子數為1至4的無水或低級醇(甲醇、乙醇、丙醇、丁醇等),(c)上述低級醇和水的混合溶劑,(d)丙酮,(e)乙酸乙酯,(f)氯仿,(g)乙酸丁酯,(h)1,3-丁二醇,(i)己烷及(j)二乙醚等,為了容易的提取,可利用水、乙醇或水和乙醇的混合物來提取。
並且,在本發明中利用的發酵熟成諾麗或其提取物及卡曼橘提取物,通過減壓蒸餾及冷凍乾燥或噴霧乾燥等之類的追加過程,能夠以粉末狀態製備。
在本發明中,其特徵在於,上述發酵熟成諾麗或其提取物及卡曼橘提取物的重量比為70:30至99:1,或者80:20至95: 5,或者70:30至90:10。
根據本發明的一實施方式,本發明係有關於包含發酵熟成諾麗及卡曼橘作為活性成分的食品組合物用於釋放壓力。
上述食品組合物作為一例可包含保健食品組合物,上述保健食品組合物有各種食品類、飲料、口香糖、茶、維生素複合劑、保健食品類等,能夠以粉末、顆粒、片劑、膠囊或飲料的形態使用。各劑型的食品組合物,除了活性成分以外,可根據劑型或使用目的,普通技術人員容易地適當選擇相關領域中通常使用的成分來配合,當與其他原料同時適用時,可產生提升效果。
上述組合物在不損害本發明所目的的主要效果的範圍內,可包含給主要效果可帶來提升效果的其他成分等。例如,為了改善物性,還可包含香料、色素、殺菌劑、抗氧化劑、防腐劑、保濕劑、增粘劑、無機鹽類、乳化劑及合成高分子物質等添加劑。
當本發明的保健食品組合物使用為食品添加物時,原封不動地添加上述發酵熟成諾麗、卡曼橘或者可一起使用其他食品或食品成分,根據常規方法可適當使用。活性成分的混合量可根據其使用目的(預防、健康或治療處置)適當確定。上述食品的種類不受特殊限制。作為可添加上述發酵熟成諾麗、卡曼橘的食品的例,有肉類、香腸、麵包、巧克力、糖果類、速食類、餅乾類、披薩、速食麵、其他面類、口香糖類、包含霜淇淋類的乳製品、各種湯類、飲料水、茶、補液、酒精飲料及維生素複合劑等,均包含常規意義上的保健食品。
當本發明的組合物使用為健康飲料時,如常規的飲料一樣,可包含多種香味劑或天然碳水化合物等作為追加成分。上述的天然碳水化合物為葡萄糖、果糖之類的單糖;麥芽糖、蔗糖之類的二糖;糊精、環糊精之類的多糖;木糖醇、山梨醇、赤蘚糖醇等糖醇。作為甜味劑可使用索馬甜、甜菊苷提取物之類的天然甜味劑,或者糖精或阿斯巴甜之類的合成甜味劑等。
本發明提供包含發酵熟成諾麗及卡曼橘的組合物的製備方法,其包括:獲得利用乳酸菌來將諾麗發酵及熟成的發酵熟成諾麗的步驟;以及在上述發酵熟成諾麗中追加混合卡曼橘的步驟。
根據本發明的一實施方式,本發明提供包含發酵熟成諾麗或其提取物及卡曼橘提取物的組合物的製備方法,其包括:步驟(a),獲得利用乳酸菌使諾麗發酵及熟成的發酵熟成諾麗;以及步驟(b),在上述發酵熟成諾麗中追加卡曼橘而熟成。
根據本發明的一實施方式,本發明提供壓力釋放用組合物的製備方法,其特徵在於,包括:步驟(a),在諾麗果接種乳酸菌,製備通過發酵及熟成而生物轉化的發酵諾麗;步驟(b),將上述發酵熟成諾麗榨汁;以及步驟(c),在上述發酵熟成諾麗追加卡曼橘而混合。
上述發酵及熟成,可在35至40℃下進行48至168小時。
上述熟成,以規定時間間隔,可將發酵過程中生成的發酵液撒布於發酵物的上部的方式實施。
上述生物轉化的發酵諾麗可以是諾麗果中接種上述7種乳酸菌中的任一種以上的發酵物。
根據本發明的一實施方式,本發明係有關於包含發酵熟成諾麗或其提取物及卡曼橘提取物作為活性成分的藥學組合物用於釋放壓力或預防、治療壓力疾病。
在本發明中,確認作為壓力激素的皮質醇的分泌被抑制,由此也抑制因壓力引起的行動變化,故而可知呈現抑鬱症、焦慮症、疲勞綜合征、睡眠障礙、恐慌障礙、記憶力減退、無力症、不眠症、帕金森氏病及阿爾茨海默病等壓力疾病的預防或治療的效果。
因此,本發明係有關於包含發酵熟成諾麗或其提取物及卡曼橘提取物作為活性成分的藥學組合物用於預防、治療壓力疾病。
根據本發明的藥學組合物,單獨包含活性成分或者能夠以適合的形態一起劑型化藥學上允許的載體,並可追加包含賦形劑或稀釋劑。上述“藥學上允許的”在生理學上允許並給藥到人體時,通常是指不引起胃腸障礙、眩暈症等之類的過敏反應或與其類似的反應的非毒性的組合物。
作為藥學上允許的載體,例如可追加包含口服用載體或非口服用載體。口服用載體可包含乳糖(lactose)、澱粉(starch)、澱粉纖維素衍生物(cellulose derivatives)、硬脂酸鎂(magnesium stearate)、硬脂酸(stearic acid)等。而且,可包含針對肽製劑的使用為口服用的多種藥物傳遞物質。並且,非口服用載體可包含水、適合的油、生理鹽水(saline)、水性葡萄糖(aqueous glucose)及乙二醇(glycol)等,並可追加包含穩定劑及保存劑。作為適合的穩定劑有亞硫酸氫鈉(sodium hydrogen sulfite)、亞硫酸鈉(sodium sulfite)或抗壞血酸(ascorbic acid)之類的抗氧化劑。適合的保存劑有氯化苯甲烴銨(benzalkonium chloride)、尼泊金甲酯或尼泊金丙酯(methyl- or propyl-paraben)及氯丁醇(chlorobutanol)。本發明的藥學組合物,除了上述成分以外可追加包含潤滑劑、濕潤劑、甜味劑、香味劑、乳化劑、懸浮劑等。另外藥學上允許的載體及製劑可參照以下文獻中記載的內容(Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995)。
本發明的組合物,通過任何方法也能給藥到包括人在內的哺乳動物中。例如,能夠口服或非口服給藥。非口服給藥方法不限定於此,但是可以是靜脈內、肌肉內、動脈內、骨髓內、硬膜內、心臟內、經皮、皮下、腹腔內、鼻腔內、腸管、局部或舌下或直腸內給藥。
本發明的藥學組合物根據如上所述的給藥途徑可劑型化為口服用或非口服用製劑。
就口服用製劑而言,本發明的組合物可利用本領域公知的方法劑型化為粉末、顆粒、片劑、丸劑、糖衣片劑、膠囊劑、液劑、凝膠劑、糖漿劑、漿料劑、懸浮液等。例如,口服用製劑,將活性成分與固體賦形劑配合之後將其粉碎,添加適合的補助劑之後,加工為顆粒混合物,由此可獲得片劑或糖衣片劑。作為適合的賦形劑的例,可包含乳糖、葡萄糖、蔗糖、山梨糖醇、甘露醇、木糖醇、赤蘚糖醇及麥芽糖醇等的糖類、包含玉米澱粉、麥澱粉、米澱粉及土豆澱粉等的澱粉類、包含纖維素、甲基纖維素、羧甲基纖維素鈉及羥丙基甲基-纖維素等的纖維素類、明膠、聚乙烯吡咯烷酮等之類的填充劑。並且,根據情況,可添加作為崩解劑的交聯聚乙烯吡咯烷酮、瓊脂、海藻酸或海藻酸鈉等。進而,本發明的藥學組合物還可包含抗凝集劑、潤滑劑、濕潤劑、香料、乳化劑及防腐劑等。
對於非口服用製劑而言,通過本領域的公知的方法,能夠以注射劑、膏化劑、乳液劑、外用軟膏劑、油劑、保濕劑、凝膠劑、氣溶膠及鼻腔吸入劑的形態進行劑型化。這些劑型記載於所有制藥化學中通常公知的處方文獻(Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, PA,1995)。
本發明的組合物的總有效量,能夠以單劑量(single dose)給藥到患者,並可通過以多劑量(multiple dose)長期給藥的分次治療方法(fractionated treatment protocol)給藥。本發明的藥學組合物,可根據疾病的程度來改變活性成分的含量。較佳地,對於本發明的藥學組合物的較佳的整體容量而言,按患者體重每1kg,每天可以是約0.01μg以是至10000mg,較佳地可以是0.1μg可以至500mg,最較佳地可以是100mg至500mg。但是,上述藥學組合物的容量,不僅考慮製劑化方法、給藥途徑及治療次數,而且也考慮患者的年齡、體重、健康狀態、性別、疾病的重症度、飲食及排泄率等多種因素來確定有關患者的有效劑量,因此當考慮到這個問題時,只要是本技術領域的普通技術人員就能確定本發明的組合物的適當的有效劑量。根據本發明的藥學組合物,只要呈現本發明的效果,其劑型、給藥途徑及給藥方法就不受特殊限制。
根據本發明的一實施方式,本發明係有關於包含發酵熟成諾麗或其提取物及卡曼橘提取物的壓力釋放用或壓力疾病的預防或治療用醫藥外品組合物。
本發明中使用的術語“醫藥外品”是指出於診斷、治療、減輕或預防人或動物的疾病的目的來使用的物品中除了不是器具、機械或裝置的物品以及出於給人或動物的結構和功能帶來藥理學影響的目的使用的物品中除了不是器具、機械或裝置的物品,作為一個具體例,可包含內服用製劑,但並不限定於此,醫藥外品的製劑化方法、容量、利用方法、結構成分等可從技術領域中公知的常規技術中適當選擇。
本發明的醫藥外品組合物,除了上述成分以外,根據需要還可包含藥學上允許的載體、賦形劑或稀釋劑。上述藥學上允許的載體、賦形劑或稀釋劑,只要不損害本發明的效果,就不受限制,例如,可包含填充劑、增量劑、結合劑、濕潤劑、崩解劑、表面活性劑、潤滑劑、甜味劑、芳香劑、保存劑等。
根據本發明的一實施方式,本發明係有關於包含發酵熟成諾麗或其提取物及卡曼橘提取物的壓力釋放用或壓力疾病的預防或治療用飼料組合物。
在本發明中,上述飼料組合物,能夠以常規的飼料形態進行劑型化,並可一同包含公知的飼料成分。並且,還可以使用為所用到的飼料中以添加劑形態添加的飼料添加劑。本發明的飼料添加劑相當於飼料管理法上的補助飼料,還可包含重碳酸鈉(蘇打(soda))、膨潤土(bentonite)、氧化鎂、複合礦物質等礦物質製劑,作為鋅、銅、鈷、硒等微量礦物質的礦物製劑,胡蘿蔔素、維生素E、維生素A、D、E、煙酸、維生素B複合體等維生素製劑,蛋氨酸、賴氨酸等氨基酸保護劑,脂肪酸鈣鹽等脂肪酸保護劑,益生菌(乳酸菌製劑)、酵母培養物、黴菌發酵物等益生菌、酵母劑等。
本發明的飼料或飼料添加劑可適用於包括哺乳類、家禽及魚類的多個動物飼料。
[對照先前技術之功效]
根據本發明的壓力釋放用組合物中包含的發酵熟成諾麗或其提取物及卡曼橘提取物具有利用天然藥材及食品組合物來釋放壓力,並預防因壓力引起的症狀(疾病)或者無副作用地有效改善的效果。
並且,上述發酵熟成諾麗分泌在發酵諾麗果的工程中可提高消化吸收的生物轉化的成分(東莨菪素、去乙醯車葉草苷酸及車葉草苷酸),由此具有如下效果,促進消化力相對差的成人、老人的消化力並促進排便活動,另一方面,由於是天然原料,因此無毒性和副作用,由此可放心攝取。
並且,由於上述發酵熟成諾麗的製備工程簡單,因此可大幅節減製備成本,由此具有可大幅減輕消費者的購買費用負擔的效果。
並且,發酵熟成諾麗及卡曼橘複合組合物是比起以往諾麗而言,喜好度功能性得到改善,由此讓消費者無負擔地享受的食品組合物。
以下,通過以下實施例更詳細說明本發明。但是,這些實施例用於例示說明本發明,本發明的範圍並不僅限定於這些實施例。
實施例1:壓力釋放用組合物製備
根據本發明的組合物,通過如下過程製備。
1.1:發酵熟成諾麗的製備
在諾麗果690kg接種複合乳酸菌(7種複合乳酸菌,AON1805(株),Lactomason Co., Ltd.),在37℃下發酵45天以上。從發酵起始日起,每7天收集10L發酵液,倒在諾麗果上側並使其覆蓋,以實施發酵及熟成。此時,使用的複合乳酸菌(7種複合乳酸菌,AON1805(株),Lactomason Co., Ltd.)的組成如以下表1所示。
熟成結束之後,將上述發酵熟成諾麗榨汁,去除固體,獲得發酵熟成諾麗提取物。
[表1]
原材料名或成分名及配合比率 | ||
No. | 原材料名或成分名 | 配合比率(%) |
1 | 植物乳桿菌(Lactobacillus plantarum) | 70% |
2 | 鼠李糖乳桿菌(Lactobacillus rhamnosus) | 5% |
3 | 乾酪乳桿菌(Lactobacillus casei) | 5% |
4 | 發酵乳桿菌(Lactobacillus fermentum) | 5% |
5 | 副乾酪乳桿菌(Lactobacillus paracasei) | 5% |
6 | 羅伊氏乳桿菌 (Lactobacillus reuteri) | 5% |
7 | 乳酸乳球菌乳酸亞種(Lactococcus lactis subsp. lactis) | 5% |
1.2:卡曼橘提取物的製備
在本實驗例中使用的卡曼橘是購買市面上銷售的卡曼橘來使用。冷凍或乾燥卡曼橘是購買市面上銷售的冷凍或乾燥卡曼橘來使用。
上述冷凍卡曼橘,通過粉碎、榨汁而製備提取物。在乾燥卡曼橘100g中加入重量份的10倍水之後,在50℃下8小時之內提取2次之後,利用濾紙過濾提取液。在37~40℃的水浴,使用旋轉真空蒸發器(rotary vacuum evaporator)(EYELA A-1000S, Tokyo Rikakikai Co., Tokyo, Japan),去除濾液中的水,製備提取物,將其使用為飼料。
上述卡曼橘的不同樣品不同提取溶劑提取產率如以下[表2]所示。
[表2]
樣品 | 提取物 | 產率(%) |
乾燥卡曼橘(DCE) | 水提取物 | 13.2 |
冷凍卡曼橘(FCE) | 榨汁提取物 | 15.3 |
1.3 :利用發酵熟成諾麗提取物和卡曼橘提取物的複合物的製備
以通過上述1.1至1.2製備的發酵熟成諾麗提取物、卡曼橘提取物的不同配合比混合之後,熟成15天,製備複合物。
[複合物的製備]
複合物1:發酵熟成諾麗提取物(重量百分比)90:乾燥卡曼橘提取物(重量百分比)10
複合物2:發酵熟成諾麗提取物(重量百分比)80:乾燥卡曼橘提取物(重量百分比)20
複合物3:發酵熟成諾麗提取物(重量百分比)70:乾燥卡曼橘提取物(重量百分比)30
複合物4:發酵熟成諾麗提取物(重量百分比)90:冷凍卡曼橘提取物(重量百分比)10
複合物5:發酵熟成諾麗提取物(重量百分比)80:冷凍卡曼橘提取物(重量百分比)20
複合物6:發酵熟成諾麗提取物(重量百分比)70:冷凍卡曼橘提取物(重量百分比)30
實驗例1:確認本發明的組合物對壓力釋放帶來的影響
確認通過上述實施例1.1至1.2製備的單一提取物和通過實施例1.3製備的複合物對壓力釋放能力帶來的影響。
(1)小白鼠試驗對象
4周齡的ICR雄性小鼠(奧源生物,韓國(Orient Bio, Korea))經過一周的適應期間之後,按12小時單位重複照明設備的點燈及滅燈,在維持室內溫度18至23℃、濕度60%的空間適應一周之後,將實驗動物如下分類為各個8隻。作為飼料供給固體飼料,除了誘導壓力的過程以外,不限定於飼料及供水。
實驗組1(正常對照組,以下由Normal表示)、實驗組2(陰性對照組,以下由Control表示)口服生理鹽水。另一方面,設置為實驗組3(發酵熟成諾麗100mg/kg給藥組,由以下FN表示)、實驗組4(乾燥卡曼橘提取物100mg/kg給藥組,由以下DCE表示)、實驗組5(冷凍卡曼橘提取物100mg/kg給藥組,由以下FCE表示)、實驗組6(複合物1 100mg/kg給藥組,由以下C 1表示)、實驗組7(複合物2 100mg/kg給藥組,由以下C 2表示)、實驗組8(複合物3 100mg/kg給藥組,由以下C 3表示)、實驗組9(複合物4 100mg/kg給藥組,由以下C 4表示)、實驗組10(複合物5 100mg/kg給藥組,由以下C 5表示)、實驗組11(複合物6 100mg/kg給藥組,由以下C 6表示),試驗物質按1次/1天總共給藥4周。
(2)誘導壓力
以上試驗對象的陰性對照組使用生理鹽水,實驗組1、實驗組2、實驗組3、實驗組4、實驗組5及實驗組6從單一提取物或複合物給藥7天後起4周內每天誘導壓力。壓力誘發方法修改Willner等(Wilner et al., Reduction fo sucrose preference by chronic unpredictable mild stress, 1987)的方法來使用,具體地造成禁食、禁食以後的飲食限制(供給少量的飼料)、禁水、提供禁水以後的空瓶、傾斜的飼養場、一個飼養場內飼養多隻實驗動物、閃爍的燈光、陰冷的房屋、持續的燈光等之類的預測不到的多種精神壓力狀況,由此誘導壓力。
(3)強迫游泳實驗(Forced Swimming test)
通過實驗動物對象實施強迫游泳實驗。在圓筒形透明水槽(直徑14cm,高度20cm)中填充23~25℃的水,直至水深達到15cm為止,然後將每一隻實驗動物放到水槽內。使所有實驗動物在圓筒形水槽中強迫游泳6分鐘。開始後,2分鐘被視為適應時間,在結束前4分鐘內,測定使實驗動物在圓筒形水槽內不動的總時間(以下,稱為“不動時間”)並記錄。
具體地,所謂不動時間是指除了抬頭至水面上的程度的小動作以外,沒有任何動作的狀態(不動性)。不動性是抑鬱症的絕望指標中之一,是在壓力實驗動物中能夠經常見到的。
如圖1所示,調查到陰性對照組(Control)的不動時間相比於正常對照組(Normal)更長。與此相反,實驗組3的不動時間相比於正常對照組稍微長,但是可知相比於陰性對照組,不動時間以80%水準更短。反之,實驗組4及5與陰性對照組相比時,呈現顯著差異,並調查到給藥發酵熟成諾麗和卡曼橘複合物的實驗組(6、7、8、9、10及11)的不動時間相比於陰性對照組顯著地以一半水準減少。因此,可知比起發酵熟成諾麗或卡曼橘單一提取物,複合物對不動時間的減少更有效果。
(4)懸尾實驗(Tail Suspension Test)
通過實驗動物對象實施2次懸尾實驗。從底部到15cm高度抓住實驗動物尾巴的1cm末端,將實驗動物倒掛6分鐘,觀察實驗動物的動作。初期2分鐘被視為適應時間,在結束前4分鐘內,測定實驗動物不動的時間並記錄。
如圖2所示,調查到陰性對照組(Control)的將懸尾倒掛的狀態下的不動時間相比於正常對照組(Normal)更長。這因精神壓力導致不動時間增加,並意味著挫折感增加。
實驗組3(FN)的不動時間以82%水準相比於陰性對照組(Control)短,身體較為動彈,但是實驗組4的不動時間以92%水準相比於陰性對照組呈現顯著差異。
並且,調查到以規定比率混合發酵熟成諾麗提取物(FN)和卡曼橘提取物(DCE & FCE)提取物而製備的複合物(1、2、3、4、5及6)實驗組均相比於陰性對照組顯著低。由此可知,以規定比率混合發酵熟成諾麗及卡曼橘提取物的複合物,對因壓力引起的無力症及挫折感緩解更有效果。
實驗例2:固定壓力誘導小白鼠的基於組合物攝取的血中IgA水準變化實驗
在狹窄的框中,每天2小時共21天不讓小白鼠動彈而被誘發壓力的固定壓力誘發8周齡C57BL/6小鼠每天口服100mg/kg以規定比率混合發酵熟成諾麗提取物(FN)、卡曼橘提取物(CE)、發酵熟成諾麗提取物(FN)和卡曼橘提取物(DCE & FCE)提取物而製備的複合物(1、2、3、4、5及6)。
如圖3所示,血清中IgA水準的測定結果,呈現發酵熟成諾麗提取物給藥組(FN)、複合物1、複合物4給藥組相比於對照組(control),統計學上顯著增加的IgA水準。
尤其,複合物4給藥組中呈現最高的IgA水準的增加。
實驗例3:固定壓力誘發小白鼠的基於複合物攝取的體重變化實驗
將以規定比率混合發酵熟成諾麗提取物(FN)、卡曼橘提取物(CE)、發酵熟成諾麗提取物(FN)和卡曼橘提取物(DCE & FCE)提取物而製備的複合物(1、2、3、4、5及6)每天100 mg/kg口服給每天2小時共21天誘發固定壓力的8周齡C57BL/6。
如圖4所示,體重變化的測定結果,固定對照組(control)的體重相比於正常組(Normal)減少,發酵熟成諾麗提取物(FN)、複合物1及4給藥組的體重減少相比於固定對照組(control)更低。
尤其,複合物1及4中呈現最低的體重減少。
實驗例4:固定壓力誘發小白鼠的基於複合物攝取的血中皮質醇(Cortisol)和血清素(Serotonin)生產量變化測定實驗
將以規定比率混合發酵熟成諾麗提取物(FN)、卡曼橘提取物(CE)、發酵熟成諾麗提取物(FN)和卡曼橘提取物(DCE & FCE)提取物而製備的複合物(1、2、3、4、5及6)每天100mg/kg口服給每天2小時共21天誘發固定壓力的8周齡C57BL/6。
血清中感到快樂情感的激素即血清素(Serotonin)水準的測定結果,呈現發酵熟成諾麗提取物(FN)100 mg/kg(p<0.05)以及發酵熟成諾麗提取物(FN)、複合物1及複合物4給藥組相比於固定對照組(Control),統計學上顯著增加的血清素(Serotonin)水準(圖5)。
血清中壓力激素即皮質醇(Cortisol)水準的測定結果,呈現發酵熟成諾麗提取物(FN)以及複合物1及4給藥組相比於固定對照組(control),統計學上顯著減少的皮質醇(Cortisol)水準(圖6)。
尤其,複合物1及4中呈現最高的血清素水準的增加和最高的皮質醇水準的減少。
由以上的說明應當可理解本發明所屬技術領域的普通技術人員在不變更技術思想或必需特徵的情況下能夠將本發明實施為其他具體方式。與此相關的是,應當要理解以上描述的實施例在整體方面上是示例性的,而不是限定性的。本發明的範圍比起上述詳細的說明,應當要理解所附的權利要求書的意思及範圍及其等同概念中導出的所有變更或變形的方式包括在本發明的範圍內。
圖1為在強迫游泳實驗中表示本發明的對照組(control)、單一組及基於複合組合物攝取的實驗動物不動時間的圖表;
圖2為在懸尾實驗中表示本發明的對照組(control)、單一組及基於複合組合物攝取的實驗動物的不動時間的圖表;
圖3為在固定壓力誘發小白鼠中表示本發明的對照組(control)、單一組及基於複合組合物攝取的血中IgA水準變化實驗結果圖表;
圖4為在固定壓力誘發小白鼠中表示本發明的對照組(control)、單一組及基於複合組合物攝取的體重變化實驗結果圖表;
圖5為在固定壓力誘發小白鼠中表示本發明的對照組(control)、單一組及基於複合組合物攝取的血清素生產量變化實驗結果圖表;
圖6為在固定壓力誘發小白鼠中表示本發明的對照組(control)、單一組及基於複合組合物攝取的血中皮質醇生產量變化實驗結果圖表。
Claims (12)
- 一種用於釋放壓力或用於壓力的預防或治療的食品組合物,其特徵在於,作為一活性成分包含發酵熟成諾麗或其提取物,及卡曼橘提取物。
- 如請求項1所述的食品組合物,其中,該發酵熟成諾麗或其提取物及卡曼橘提取物的重量比為70:30至99:1。
- 如請求項1所述的食品組合物,其中,該發酵熟成諾麗或其提取物是利用乳酸菌將諾麗進行發酵及熟成而獲得的發酵熟成諾麗。
- 如請求項1至3之中任一項所述的食品組合物,其中,該食品組合物為保健食品。
- 如請求項1所述的食品組合物,其中,該食品組合物為選自粉末、顆粒、丸、片劑、膠囊、糖果、糖漿及飲料中的任一種劑型。
- 一種用於釋放壓力或用於壓力的預防或治療的藥學組合物,其特徵在於,作為一活性成分包含發酵熟成諾麗或其提取物,及卡曼橘提取物。
- 一種用於釋放壓力或用於壓力的預防或治療的醫藥外品組合物,其特徵在於,作為一活性成分包含發酵熟成諾麗或其提取物,及卡曼橘提取物。
- 一種用於釋放壓力的飼料組合物,其特徵在於,作為一活性成分包含發酵熟成諾麗或其提取物,及卡曼橘提取物。
- 一種包含發酵熟成諾麗或其提取物及卡曼橘提取物的組合物的製備方法,其特徵在於,包括: 步驟(a),利用乳酸菌將諾麗進行發酵及熟成,以獲得發酵熟成諾麗;以及 步驟(b),在該發酵熟成諾麗中追加卡曼橘而熟成。
- 如請求項9所述的製備方法,其中,在該步驟(a)之後,還包括將所得的發酵熟成諾麗榨汁而獲得發酵熟成諾麗提取物的步驟。
- 一種組合物,其特徵在於,其根據請求項9所述的製備方法獲得。
- 如請求項11所述的組合物,其中,該組合物具有釋放壓力能力。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0185599 | 2020-12-29 | ||
KR20200185599 | 2020-12-29 | ||
KR1020210166914A KR102686309B1 (ko) | 2020-12-29 | 2021-11-29 | 발효숙성노니 및 깔라만시를 유효성분으로 포함하는 스트레스 완화용 조성물 |
KR10-2021-0166914 | 2021-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202234999A true TW202234999A (zh) | 2022-09-16 |
Family
ID=82118402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110149147A TW202234999A (zh) | 2020-12-29 | 2021-12-28 | 包含發酵熟成諾麗及卡曼橘作為活性成分的組合物用於釋放壓力 |
Country Status (4)
Country | Link |
---|---|
US (2) | US11911430B2 (zh) |
CN (1) | CN114680331A (zh) |
TW (1) | TW202234999A (zh) |
WO (1) | WO2022145893A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102151371B1 (ko) * | 2020-03-02 | 2020-09-02 | 박은영 | 발효 노니를 포함하는 당뇨 예방 및 개선용 식품 조성물 및 그 제조방법 |
CN115813797A (zh) * | 2022-10-26 | 2023-03-21 | 海南丰席树诺丽日化有限责任公司 | 一种天然诺丽果肽提取物在洗发水中的应用及制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100574236B1 (ko) * | 2003-11-22 | 2006-04-26 | 황재복 | 노니열매를 이용한 노니액기스 제조방법 |
US20080152733A1 (en) * | 2006-12-20 | 2008-06-26 | Logsdon Lawrence M | Noni juice composition |
CN101057700B (zh) * | 2007-04-17 | 2010-07-21 | 海南万维生物制药技术有限公司 | Noni发酵果汁的加工方法及Noni发酵果汁 |
KR20090072555A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 노니원 | 노니열매의 농축액 제조방법 |
WO2016038841A1 (ja) * | 2014-09-10 | 2016-03-17 | 森 昌朋 | 食欲抑制組成物 |
CN104667109B (zh) * | 2015-03-19 | 2017-11-17 | 海南大学 | 一种药物组合物、保健品及制备方法 |
KR20180019847A (ko) * | 2016-08-17 | 2018-02-27 | (주)보뚜슈퍼푸드 | 흰점박이꽃무지 유충 추출물 및 칼라만시 추출물을 유효성분으로 하는 항비만 조성물 |
CN106360200A (zh) * | 2016-08-25 | 2017-02-01 | 贵州北极熊实业有限公司 | 苏打水饮料及其制作方法 |
CN109943422A (zh) * | 2017-12-21 | 2019-06-28 | 株式会社昌平 | 天然皂组合物 |
KR102662426B1 (ko) * | 2018-10-08 | 2024-04-30 | 박은영 | 유산균 발효숙성 노니와 코코넛 슈가를 포함하는 유산균 발효 노니 식초의 제조방법 |
KR102138976B1 (ko) * | 2018-10-08 | 2020-07-28 | 박은영 | 발효 숙성 노니 열매를 포함하는 건강기능성 식품용 노니 파우더의 제조방법 |
KR102149101B1 (ko) * | 2018-12-19 | 2020-10-13 | (주)애터미오롯 | 노니 주스의 이취억제 및 유효성분이 강화된 발효농축액 및 그 제조방법 |
KR102047627B1 (ko) * | 2019-05-16 | 2019-12-04 | 구경회 | 노니를 포함하는 과채음료의 제조방법 및 이에 의하여 제조되는 노니를 포함하는 과채음료 |
KR102151372B1 (ko) * | 2020-03-02 | 2020-09-02 | 박은영 | 발효 노니를 포함하는 남성 갱년기 증후군 예방 및 개선용 식품 조성물 및 그 제조방법 |
KR102151371B1 (ko) * | 2020-03-02 | 2020-09-02 | 박은영 | 발효 노니를 포함하는 당뇨 예방 및 개선용 식품 조성물 및 그 제조방법 |
-
2021
- 2021-12-24 WO PCT/KR2021/019834 patent/WO2022145893A1/ko active Application Filing
- 2021-12-28 TW TW110149147A patent/TW202234999A/zh unknown
- 2021-12-28 CN CN202111632200.5A patent/CN114680331A/zh active Pending
- 2021-12-29 US US17/646,467 patent/US11911430B2/en active Active
-
2023
- 2023-04-14 US US18/300,482 patent/US12064462B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20230248796A1 (en) | 2023-08-10 |
US20220202893A1 (en) | 2022-06-30 |
US11911430B2 (en) | 2024-02-27 |
US12064462B2 (en) | 2024-08-20 |
CN114680331A (zh) | 2022-07-01 |
WO2022145893A1 (ko) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5686496B2 (ja) | メタボリックシンドローム改善・予防組成物 | |
US12064462B2 (en) | Composition for stress relief containing fermented ripened noni and calamansi extract as active ingredients | |
JP6345243B2 (ja) | 円武扇発酵物含有食品または飲料組成物 | |
KR101614574B1 (ko) | 탱자 발효물에 의한 비만개선효과물질의 조성 | |
JP2005170837A (ja) | 海藻抽出物およびそれを含む糖質加水分解酵素阻害剤 | |
JP2018516987A (ja) | 阿魏茸の水抽出物を有効成分として含有する代謝性疾患の予防及び治療用薬学的組成物又は健康機能性食品 | |
JP2015502954A (ja) | アギタケの水抽出物を有効成分として含有する脂質異常症の予防又は治療用の組成物 | |
KR20180134161A (ko) | 타트체리추출물 및 미배아발효추출물을 유효성분으로 포함하는 우울증 또는 불안증 예방, 개선 또는 치료용 조성물 | |
WO2005094858A1 (ja) | 抗糖尿病用組成物 | |
WO2005056034A1 (ja) | 海藻抽出物およびそれを含むリパーゼ阻害剤 | |
KR20120097080A (ko) | 백운풀 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 치료용 조성물 | |
KR101207239B1 (ko) | 천문동 추출물로부터 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물 | |
JP2014051436A (ja) | α−アミラーゼ阻害剤 | |
KR102686309B1 (ko) | 발효숙성노니 및 깔라만시를 유효성분으로 포함하는 스트레스 완화용 조성물 | |
KR20230095471A (ko) | 오미자박 발효물을 유효성분으로 포함하는 근력개선용 조성물 및 그의 제조방법 | |
KR101757841B1 (ko) | 바이칼린-아연착염을 포함하는 비만억제용 조성물 | |
JP5362976B2 (ja) | 血流改善剤 | |
KR100887234B1 (ko) | 상황버섯 추출물을 포함하는 당뇨병 합병증 치료 또는예방용 조성물 | |
KR102485676B1 (ko) | 구멍갈파래 추출물을 포함하는 비만의 개선, 예방 또는 치료용 조성물 | |
TW202228754A (zh) | 包含發酵熟成諾麗、椰子糖或黑砂糖活性成分的組合物用於增進運動能力及疲勞恢復 | |
EP3620166B1 (en) | Composition for anti-obesity comprising the pulverized material of odontella aurita as an active ingredient | |
KR20130058388A (ko) | 발효 맥문동 추출물을 유효성분으로 포함하는 항산화 조성물 | |
KR101954890B1 (ko) | 해마 추출물을 포함하는 비알코올성 지방간 치료 또는 개선용 조성물 | |
KR20220097222A (ko) | 발효숙성노니, 코코넛 슈가 또는 모스코바도 슈가를 유효성분으로 포함하는 운동수행능력 및 피로회복 증진용 조성물 | |
KR20150024159A (ko) | 가바(감마-아미노부티르산) 함량이 증가된 쌀 추출물의 제조방법 및 상기 추출물을 포함하는 조성물 |